Cellular Pathology, North Bristol NHS Trust, Westbury on Trym, Bristol, UK.
Cellular Pathology, North Bristol NHS Trust, Westbury on Trym, Bristol, UK
J Clin Pathol. 2021 May;74(5):327-330. doi: 10.1136/jclinpath-2020-206726. Epub 2020 Nov 18.
To examine the effects of specialist reporting on error rates in prostate core biopsy diagnosis.
Biopsies were reported by eight specialist uropathologists over 3 years. New cancer diagnoses were double-reported and all biopsies were reviewed for the multidisciplinary team (MDT) meeting. Diagnostic alterations were recorded in supplementary reports and error rates were compared with a decade previously.
2600 biopsies were reported. 64.1% contained adenocarcinoma, a 19.7% increase. The false-positive error rate had reduced from 0.4% to 0.06%. The false-negative error rate had increased from 1.5% to 1.8%, but represented fewer absolute errors due to increased cancer incidence.
Specialisation and double-reporting have reduced false-positive errors. MDT review of negative cores continues to identify a very low number of false-negative errors. Our data represents a 'gold standard' for prostate biopsy diagnostic error rates. Increased use of MRI-targeted biopsies may alter error rates and their future clinical significance.
研究专家报告对前列腺核心活检诊断错误率的影响。
在 3 年期间，8 位泌尿科专家对活检进行了报告。新的癌症诊断结果进行了双重报告，所有活检均在多学科团队（MDT）会议上进行了复查。在补充报告中记录了诊断变更，并且将错误率与十年前进行了比较。
报告了 2600 例活检。腺癌占 64.1%，增加了 19.7%。假阳性错误率已从 0.4%降至 0.06%。假阴性错误率从 1.5%增加到 1.8%，但由于癌症发病率的增加，绝对错误数量减少。
专业化和双重报告减少了假阳性错误。MDT 对阴性核心的复查继续发现极少数假阴性错误。我们的数据代表了前列腺活检诊断错误率的“金标准”。MRI 靶向活检的广泛应用可能会改变错误率及其未来的临床意义。
